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Abstract 
As a continuation of our studies on 2-phenylindol-3-ylglyoxylamides as potent and selective 
Translocator Protein (TSPO) ligands, two subsets of novel derivatives, featuring hydrophilic group 
(OH, NH2, COOH) at the para-position of the pendant 2-phenyl ring (8-16) or different 2-aryl 
moieties, namely 3-thienyl, p-biphenyl, 2-naphthyl, (23-35), were synthesized and biologically 
evaluated, some of them showing Ki values in the subnanomolar range and the 2-naphthyl group 
performance being the best. The resulting SARs confirmed the key role played by interactions 
taking place between ligands and the lipophilic L1 pocket of the TSPO binding site. Docking 
simulations were performed on the most potent compound of the present series (29) exploiting the 
recently available 3D structures of TSPO bound to its standard ligand (PK11195). Our theoretical 
model was fully consistent with SARs of the newly investigated as well of the previously reported 
2-phenylindol-3-ylglyoxylamide derivatives.  
  
Introduction 
The Translocator Protein (TSPO), first described as peripheral benzodiazepine receptor (PBR),1,2 is 
an 18 kDa protein mainly expressed in the outer mitochondrial membranes, where it interacts with a 
number of associated proteins including the voltage-dependent anion channel (VDAC, 32 kDa), the 
adenine nucleotide transporter (ANT, 30 kDa), the PBR associated protein-1 (PRAX-1, 220-250 
kDa), the steroidogenesis regulatory protein (StAR, 37 kDa), and the TSPO and protein kinase A 
regulatory subunit RIα-associated protein (PAP7, 52 kDa).1 Additional cellular locations of TSPO 
have been identified such as nucleus, lysosome, Golgi apparatus, peroxisomes, and plasma 
membrane.1,3 TSPO is an evolutionarily well-conserved and tryptophan-rich 169 amino acids 
protein organized into five transmembrane helices linked by hydrophobic loops, with a carboxy-
terminal and a short amino-terminal tails located outside and inside the mitochondria, respectively.1 
Site-directed mutagenesis experiments,4 together with a recent NMR study,5 demonstrated that the 
portion of the receptor that recognizes the ligands is located at the bottom of the transmembrane 
bundle, also contacting the first cytoplasmatic loop. 
TSPO is involved in numerous cellular processes related to the regulation of mitochondrial 
cholesterol translocation, porphyrin transport and heme synthesis, cellular proliferation and 
apoptosis, regulation of mitochondrial functions, immunomodulation and inflammation.1,4,6 This 
protein is ubiquitously expressed, with higher levels in tissues that produce steroids and that are 
mitochondrially enriched such as myocardium, skeletal muscle, and renal tissue;1 other peripheral 
tissues, including liver and lung, express TSPO to a less extent.1 In the central nervous system 
(CNS), TSPO is mainly located in glial cells, but it is also present in neurons.7 Such a distribution in 
the CNS may be related to the crucial role that TSPO plays in the regulation of cholesterol 
translocation from the outer to the inner mitochondrial membrane, where it is converted into 
pregnenolone, the precursor of all neurosteroids.8 A number of these endogenous molecules, such as 
pregnenolone and allopregnanolone, are able to rapidly inhibit neuron excitability as a result of a 
 positive allosteric modulation of type A receptors for GABA (GABAA), the major inhibitory 
neurotransmitter in the brain.9 
Altered expression of TSPO has been linked to multiple diseases, including anxiety, cancer, 
ischemia-reperfusion injury, brain injury, and neurodegenerative conditions such as Alzheimer’s 
and Parkinson’s diseases.10 In this view, TSPO ligands have potential as diagnostic tools for the 
state and progression of these related-diseases,10,11 as well as therapeutic antiproliferative and 
neuroprotective agents.12-14 
Since identification of TSPO by means of the benzodiazepines diazepam and Ro5−4864 1 (Chart 
1),2 structurally different classes of highly potent and selective ligands have been reported (Chart 1), 
including the isoquinolinecarboxamides, of which the 1-(2-chlorophenyl)-N-methyl-N-(1-
methylpropyl)-1-isoquinolinecarboxamide (PK11195, 2) is widely considered as a prototypical 
TSPO ligand,15 imidazopyridines (alpidem, 3), indoleacetamides (FGIN-1-27, 4),16 
tetrahydrocarbazolecarboxamides (GE-180, 5),17-19 and purineacetamides (AC-5216, 6).20-24 
In this context, we disclosed the N,N-dialkyl-2-phenylindol-3-ylglyoxylamides 7 as a class of potent 
and selective TSPO ligands (Chart 1), the majority of which showed Ki values in the 
nanomolar/subnanomolar range and were able to stimulate steroid biosynthesis in rat C6 glioma 
cells to an extent similar to or higher than that of classic TSPO ligands Ro5-4864, and PK11195.25-
27 A large number of derivatives 7 was synthesized and biologically evaluated, featuring different 
combinations of R1-R5 substituents. The structure-affinity relationships (SARs) of these compounds 
were rationalized in light of a pharmacophore/topological model made up of three lipophilic 
pockets (L1, L3, and L4) and an H-bond donor group H1 (Chart 1).25,26,28 According to our model, 
the amide carbonyl oxygen of the oxalyl bridge engages an H-bond with the donor site H1; the two 
lipophilic substituents on the amide nitrogen, R1, and R2 interact through hydrophobic contacts with 
the L3 and/or L4 lipophilic pockets; the 2-phenyl moiety establishes a putative π-stacking 
interaction within the L1 pocket. The optimum binding affinity to TSPO in series 7 requires two 
lipophilic substituents on the amide nitrogen (R1, R2 = methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-
 hexyl, benzyl, etc.) to fit both in the L3 and L4 lipophilic pockets. Symmetrically (R1 = R2) and 
asymmetrically (R1 ≠ R2) N,N-disubstituted indoles were investigated revealing that: (i) an aromatic 
moiety (R1/R2) is equivalent to an aliphatic one of similar size in taking hydrophobic contacts with 
the L3 or L4 lipophilic pocket; (ii) the L3 and L4 pockets are probably different in their dimensions 
as substitution pattern on the amide nitrogen with R1 and R2 of different sizes yielded high affinity 
derivatives. Moreover, the R3 substituent has to feature electron-withdrawing properties to reinforce 
the putative π-stacking interaction within the L1 pocket, and R4 has to be both electron-withdrawing 
and very small for optimal binding, a combination of properties only featured by the fluorine atom. 
Conversely, substitutions at position 7 of the indole nucleus (R5) do not produce any affinity 
gain.25,26 
As stated above, TSPO may also represent a marker for related disease progression, so that the 2-
phenylindolylglyoxylamide scaffold has been studied as a novel chemotype for the development of 
specific TSPO molecular probes. Novel reversible and irreversible fluorescent probes targeting 
TSPO were developed which featured the 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD) group as a 
fluorophore.29,30 Furthermore, a new 11C-radiolabeled probe from class 7, the N,N-di-n-propyl-(N1-
methyl-2-(4'-nitrophenyl)indol-3-yl)glyoxylamide, was synthesized and evaluated with positron 
emission tomography in monkey, showing to enter brain and give a high proportion of TSPO-
specific binding, auguring well for its future application in humans as biomarker of 
neuroinflammation.31 
As a continuation of our studies on 2-phenylindol-3-ylglyoxylamides as potent and selective TSPO 
ligands, our attention has been now focused on the effects on binding affinity of different aryl 
moieties at the 2-position of the indole nucleus. The aim of our project was to probe the L1 
lipophilic pocket and its surroundings to better define the whole topology of the TSPO binding site. 
For this purpose, a first subset of novel indole derivatives (8-16) were designed, featuring 
hydrophilic group (OH, NH2, COOH) at the para-position of the pendant 2-phenyl ring. Actually, 
Trapani and colleagues reported that the introduction of polar and ionisable substituents at the para-
 and meta-positions of the 2-phenyl ring of 2-phenylimidazopyridine TSPO ligands, yielded 
compounds showing very high affinity and selectivity for TSPO, with Ki values in the low 
nanomolar/subnanomolar range.32 To expand the SARs, derivatives 17-22 (Ar = p-CH3O-C6H4 and 
p-CH3OOC-C6H4, respectively), which are the intermediates in the synthesis of compounds 8-10 
and 14-16 (see Scheme 1), were biologically evaluated. The second subset is represented by indoles 
23-35, which are functionalized at 2-position with aryl moieties different from the variously 
substituted phenyl ring, that is 3-thienyl (23-25), and the highly steric-demanding p-biphenyl (26-
28) or 2-naphthyl (29-35) group. 
All the novel indole derivatives 8-35 were biologically evaluated for their binding affinity to TSPO.  
Finally, a 3D model of the rTSPO was developed employing the newly published NMR model of 
mTSPO (PDB code: 2MGY),5 and docking studies were conducted using compound 29 as reference 
ligand, in order to rationalize the SARs within the 2-arylindol-3-ylglyoxylamide TSPO ligands 
described so far. 
 
RESULTS AND DISCUSSION 
Chemistry. The target N,N-dialkyl-2-(4-substituted-phenyl)indol-3-ylglyoxylamides 8-16, N,N-
dialkyl-2-(thien-3-yl)indol-3-ylglyoxylamides 23-25, N,N-dialkyl-2-(p-biphenyl)indol-3-
ylglyoxylamides 26-28, and N,N-dialkyl-2-(naphth-2-yl)indol-3-ylglyoxylamides 29-35 were 
synthesized through the 2-arylindoles 36-38 and 42-44, which were in turn simply obtained, with 
the exception of the commercially 2-(biphenyl-4-yl)indole 43 and 2-(naphth-2-yl)indole 44, with a 
one-step Fischer indole synthesis by reacting phenylhydrazine hydrochloride and the appropriate 
acetyl derivative, Schemes 1 and 2. Under acid catalysis [excess of polyphosphoric acid (PPA)], the 
phenylhydrazone initially formed undergoes a number of isomerizations/rearrangements, and finally 
eliminates NH3 to give the indole products. 
Acylation of the appropriate 2-(4-substituted-phenyl)indole 36-38 with oxalyl chloride, in 
anhydrous diethyl ether, at room temperature, yielded the corresponding 2-(4-substituted-
 phenyl)indolylglyoxylyl chlorides 39-41, which were allowed to react with the appropriate 
dialkylamine, in the presence of triethylamine, in dry toluene solution, at room temperature, to give 
compounds 7d-f, 17-22 (Scheme 1).  
The indolylglyoxylamide derivatives featuring a OH group in R3 (8-10) were achieved through a 
demethylation of the methoxy group of compounds 17-19 by treatment with BBr3 in a nitrogen 
atmosphere (Scheme 1). At the end of the reaction, methanol was added to hydrolyze the excess of 
BBr3, and crude compounds were recovered as a solid precipitated after evaporation under reduced 
pressure.  
The N,N-dialkyl-[2-(4-nitrophenyl)indol-3-yl]glyoxylamide derivatives 7d-f were catalytically 
hydrogenated over palladium to yield the corresponding 2-phenylindolylglyoxylamide analogues 
11-13 bearing a NH2 in para-position at the 2-phenyl ring (Scheme 1).  
Finally, hydrolysis of the methyl ester group of compounds 20-22 with lithium hydroxide 
monohydrate, in a solution of methanol/water (3:1) gave the target compounds 14-16 (Scheme 1).  
Scheme 2 outlined the general procedure for the synthesis of N,N-dialkyl-2-(aryl)indol-3-
ylglyoxylamides 23-35. The 2-arylindoles 42-44 were acylated with oxalyl chloride, in anhydrous 
diethyl ether, at room temperature, to obtain the corresponding indolylglyoxylyl chlorides 45-47. 
The subsequent condensation with the appropriate amines, in the presence of triethylamine, in dry 
toluene solution, yielded the target derivatives 23-35. 
The reaction yields, the chemical physical constants and spectroscopic data of compounds 8-35 are 
listed in the Experimental Section. 
The (2-arylindol-3-yl)glyoxylyl chlorides 39, 41, 45-47 have never been described before in the 
literature and were characterized as their corresponding ethyl ester derivatives (see Experimental 
Section). 
Biological studies. The binding affinity of all the newly synthesized 2-arylindol-3-ylglyoxylamide 
derivatives 8-35 for the TSPO was determined by binding competition experiments against 
[3H]PK11195,25,26 carried out in rat kidney membrane homogenates (Tables 1 and 2). Because of 
 the well-established TSPO versus central benzodiazepine receptor (BzR) selectivity of N,N-dialkyl-
2-phenylindol-3-ylglyoxylamides,25,26 a few randomly selected derivatives were evaluated for their 
BzR affinity by experiments against [3H]flumazenil in rat cerebral cortex membrane 
homogenates.25,26 The tested compounds showed no significant binding properties in this assay 
(inhibition percentages at 10 μM concentration ranging from 0% to 23%, data not shown). 
The TSPO binding affinities of compounds 8-22, and 23-35, expressed as Ki values, are listed in 
Tables 1, and 2, respectively, together with the Ki values of the standard TSPO ligands Ro5-4864, 
and PK11195 (Chart 1). The binding data of some of the previously investigated indole 
derivatives25,26 are included for comparison at the bottom of Table 1 (7a-f) and Table 2 (7a-c, g-j).  
In the 8-16 series, the amide nitrogen is symmetrically disubstituted (R1 = R2, Table 1) with n-
propyl, n-butyl, and n-hexyl chains and the 2-phenyl moiety is decorated by small hydrophilic 
groups inserted at the para-position (R3 = OH, NH2, COOH, Table 1); derivatives 17-22 (R3 = 
OCH3, COOCH3, Table 1), which are the intermediates in the synthesis of compounds 8-10 and 14-
16, respectively (see Scheme 1), were also biologically evaluated to expand the SARs. 
In general, the introduction of a hydrophilic group at the para-position of the 2-phenyl ring (OH, 
NH2, COOH) did not determine any significant improvement of the affinity, suggesting that the 
interaction at the level of the L1 pocket is mostly lipophilic (Table 1). In particular, the insertion of 
an OH group at the para-position of the 2-phenyl ring is tolerated for affinity (8 Ki 16.1 nM, 9 Ki 
25.7 nM, 10 Ki 6.3 nM, vs 7a Ki 12.2 nM, 7b Ki 7.5 nM, 7c Ki 1.4 nM, respectively). Conversely, a 
decrease of the binding affinity is observed introducing a NH2 (11 Ki  44.4 nM, 12 Ki 133 nM, 13 Ki 
4.2 nM, vs 7a Ki  12.2 nM, 7b Ki 7.5 nM, 7c Ki 1.4 nM, respectively) or, to a major extent, a COOH 
group (14 Ki 343 nM, 15 Ki 406 nM, 16 Ki 184 nM vs 7a Ki 12.2 nM, 7b Ki 7.5 nM, 7c Ki 1.4 nM, 
respectively, Table 1). In addition, in all the subsets, compounds bearing n-hexyl chains on the 
symmetrically disubstituted amide nitrogen are more potent than the others. A different trend is 
observed for derivatives 17-19 and 20-22, featuring a p-methoxy and p-methoxycarbonyl 
substituent, respectively, that show, with the exception of compound 18 (Ki 20.3 nM), appreciable 
 and comparable affinity (Ki values in the low nanomolar range), whatever is the length of the side 
alkyl chains, Table 1. 
The data listed in Table 2 evidence that the replacement of the 2-phenyl group with a thien-3-yl (23-
25), a p-biphenyl (26-28), or a naphth-2-yl (29-35) moiety produces, with few exceptions, superior 
affinity TSPO ligands, with Ki values in the subnanomolar range. As the presence of a naphthyl 
group seemed to be particularly favourable for affinity, this subset was further investigated by the 
synthesis of a number of asymmetrically N,N-disubstituted indoles (32-35, Table 2), to more deeply 
probe the L3 and L4 lipophilic pockets of the TSPO binding site (R1 = methyl, ethyl; R2 = n-butyl, 
n-pentyl, benzyl). Interestingly, within the subset of the 2-(naphth-2-yl)-substituted derivatives 29-
35, all compounds showed almost identical Ki values in the subnanomolar range, ranging from 0.30 
nM to 0.56 nM (Table 2). Thus, the nature of the groups bound to the amide nitrogen does not 
significantly influence the binding of ligands 29-35 at TSPO. These data suggest a key role played 
by the lipophilic interaction at the level of the L1 pocket that, reaching its optimum with a naphthyl 
group, makes less significant the contribution to the binding of the remaining lipophilic interactions 
established by the ligand within the receptor binding site.  
Due to the well-established steroidogenic effect of derivatives from the 2-phenylindol-3-
ylglyoxylamide class,25,26 compound 29 was selected and routinely evaluated for its ability to 
stimulate pregnenolone formation from rat C6 glioma cells,25,26 showing an increase percentage in 
pregnenolone production vs control similar to that of the reference standard PK1119525,26 (see 
Supplementary Information for Method details). 
Computational Studies: rTSPO model construction and docking calculations. A survey in the 
available literature demonstrates that, to date, several X-ray33,34 and solution5 (NMR) structures 
were deposited in the Protein Data Bank (PDB).35 Among them, we decided to choose the solution 
one (mTSPO) as a template for the construction of our rTSPO model, given the higher sequence 
identity shared by the two proteins (95%). Therefore, several 3D models of the rTSPO were 
generated using the newly published NMR model of mTSPO (PDB code: 2MGY),5 by applying the 
 following protocol: (i) 20 NMR snapshots are available in the structure of the mTSPO and we used 
each of them as a template for the construction of the rTSPO; (ii) for each template, 20 models were 
generated making a total of 400 rTSPO models, grouped in 20 groups (one for each NMR 
snapshot); (iii) then, the best rTSPO models in each group were selected (i.e. the models giving the 
highest score according to the modeller native scoring function and featuring the best 
Ramachandran plots) for a total of 20 rTSPO structures. The selected 20 rTSPO models were 
refined through the protein preparation protocol available in Maestro9.8.36  
Comparison between the rTSPO model (see docking studies) and its corresponding mTSPO NMR 
snapshot template is depicted in Supplementary Figure S1 (SI), with the corresponding 
Ramachandran plots.  
Docking was performed using Glide tool of Maestro 9.836 on the 20 selected mTSPO structures. To 
set up the docking studies the following considerations were made: (i) the stoichiometry of the 
protein-ligand interaction is 1:1;5 (ii) the indolylglyoxylamide derivatives are competing for the 
same PK11195 binding site.25-27,29 On the basis of these observations, the docking studies were 
conducted on the monomeric rTSPO, and using compound 29 as reference ligand (i.e. the one 
endowed with the best binding properties). Among the 20 29/rTSPO generated complexes, we 
considered only those in which: i) the ligand was occupying the same PK11195 binding regions (17 
complexes), ii) there was agreement with the SARs reported by us in literature25-27,29,37 and in this 
work (2 complexes). Of these latter complexes, we considered the one having the highest glide 
score (1 complex) (Supplementary Figure S2, SI).  
The binding mode and the SARs of the indolylglyoxylamide derivatives. Glide software36 
predicts 29 to fairly recapitulate the experimental TSPO/ PK11195 interactions (see Supplementary 
Figure S3, SI), so that the ligand is nicely adapted in the mainly hydrophobic binding pocket of 
rTSPO (see Figure 1a). In the proposed binding mode of 29 to TSPO, the naphthyl moiety is placed 
inside a roomy aromatic cage (herein referred to as L1 pocket), establishing hydrophobic interaction 
with V110, W95, W107, L114, W143, F146 and L150 residues. This is in agreement with our 
 previous works21,22,24 25-27 showing that, among the indolylglyoxylamides, p-substitution of the 
phenyl ring at position 2 of the indole ring results in higher affinity with respect to the unsubstituted 
phenyl moiety (i.e. 7a vs 7d). Interestingly, given the aromatic/hydrophobic nature of the L1 region, 
it is not surprising that R3 polar and/or electron-donating groups are generally less tolerated than 
hydrophobic and/or electron-withdrawing ones. In particular, in the proposed binding mode (Figure 
1a-c), the aromatic ring at position 2 of the indole ring establishes a parallel displaced π-π 
interaction with W107, thus explaining the general correlation between the R3 electron-withdrawing 
effect and the affinity for rTSPO observed for the N,N-dipropyl (7d > 20 > 17 > 7a > 8 > 11 > 14) 
and for the N,N-dibutyl (7e > 21 > 7b > 18 > 9 > 12 > 15) series, but less evident for the N,N-
dihexyl one (7f > 7c > 22 > 13 > 19 > 10 > 16) (See Supplementary Figure S4, SI, for a qualitative 
correlation). This observation highlights that a cooperative effect between the nature of the 
substituents on the N,N-alkyl branches and the electronic nature of the substituents in R3 exists, and 
in turn a proper balance is required. Indeed, in the case of the N,N-dihexyl derivatives, the 
hydrophobic nature of the N,N-alkyl branches predominates over the electronic effects of the R3 
substituents.  
The extension and the chemical nature of the cleft lodging in the aforementioned group (Figure 1a-
d) would also explain why substitution with a biphenyl (26) results in comparably high affinities, 
while the presence of the smaller phenyl/thienyl groups results in lower binding (29 = 26 > 23 > 
7a).  
According to the present binding mode (Figure 1a) the N-propyl branch in the cisoid configuration 
protrudes toward the membrane environment, while the second N-propyl branch establishes 
hydrophobic interactions with V26, W107, and L150.  
The proposed theoretical model (Figure 1a) is also in agreement with our previous works where 
fluorescent probes were developed.29 In particular, we derivatized our 2-phenylindol-3-
ylglyoxylamides with a 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD) group that is well-known for 
displaying low quantum yields in water, while becoming highly fluorescent in more lipophilic 
 environments, such as membranes or hydrophobic receptor pockets.30 Indeed, according to our 
model, the attached NBD linker would be hosted outside the receptor in the membrane 
environment, thus explaining why our previously published TSPO NBD-labelled fluorescent 
probes29 are so efficient in staining rat and human glioma cells.   
The position of the N,N-disubstituted branches would also explain why bulkier substituents on the 
ligand amide moiety do not significantly affect the activity for the naphthyl derivatives (29 vs 30-
35). Interestingly, the amide branches accommodates in a similar region with respect to the amide 
branches of the PK11195 (Supplementary Figure S3, SI), and we already demonstrated in our 
previous works that bulkier substituents are well tolerated in this region.5,21,22,24,26,27,35 Differently 
from the naphthyl series (29-35), the biphenyl one seems to be affected by the presence of bulkier 
substituents on the amide branch of the glyoxylamide moiety (26 vs 27, 28). This effect can be 
explained by the different bulkiness and shape of the biphenyl moiety with respect to the naphthyl 
one (Figure 1b-d and Supplementary Figure S5, SI), which in turn does not tolerate bulkier 
substituents on the amide group.  
Furthermore, on the basis of the proposed binding mode (Figure 1a), the hydrophobic residues A23, 
W53, L49, and W143 surround the indole ring of 29. This agrees with our previous works showing 
that substitutions on position 5 and 7 of the indole ring are tolerated.25-27 Finally, in our previous 
works, based on pharmacophoric models, it was suggested that the distal carbonyl oxygen of the 
oxalyl bridge engages an H-bond with the donor site H1 of the pharmacophore/topological model 
(Chart 1), in the TSPO binding site.25-27 On the contrary, the present binding mode lacks any polar 
interaction between the glyoxylamide branch and the receptor binding site (Figure 1a). In this 
regard, it can be argued that the presence of the amide/glyoxylamide groups in TSPO binders, rather 
than engaging specific interactions with the receptor, has a role in constraining the flexibility of the 
ligand branch so as to adopt the bioactive conformation. We cannot rule out the presence of water 
molecules inside the TSPO binding pocket that mediate polar interactions between the 
amide/glyoxylamide and the protein binding site. The same interaction (H-bond with the H1 site) 
 was also postulated in a previous paper for the PK11195/TSPO pharmacophore/topological model38 
and was not lately verified by the NMR experimental structure.5 
 
CONCLUSIONS 
Novel 2-arylindol-3-ylglyoxylamides were synthesized and biologically evaluated to clarify the 
effect of different aryl moieties at the 2-position of the indole nucleus on modulation of affinity to 
TSPO, and thus to probe the L1 lipophilic pocket and its surroundings.  
Within the first subset of novel indole derivatives (8-16), the introduction of a hydrophilic group at 
the para-position of the 2-phenyl ring (OH, NH2, COOH) does not determine any significant 
improvement of the affinity; conversely, the replacement of the 2-phenyl group with thien-3-yl (23-
25), p-biphenyl (26-28), or naphth-2-yl (29-35) moiety produces, with few exceptions, superior 
affinity TSPO ligands, with Ki values in the subnanomolar range. Of note, within the subseries of 
the 2-(naphth-2-yl)-substituted derivatives 29-35, all compounds showed almost identical Ki 
subnanomolar values, independently from the nature of the groups bound to the amide nitrogen. 
Taken together, the SARs suggest a key role of the lipophilic interaction at the level of the L1 
pocket that, when reaches its optimum with a naphthyl group, makes less significant all the other 
lipophilic interactions of the molecule within the receptor protein.  
A 3D model of the rTSPO was developed employing the newly published NMR model of mTSPO 
(PDB code: 2MGY).5 Docking studies were conducted using compound 29 as reference ligand, and 
the proposed binding mode highlighted the cooperative effects between the nature of the 
substituents on the N,N-alkyl branches and the electronic features of the moiety at indole 2-position, 
rationalizing the SARs within the 2-arylindol-3-ylglyoxylamide TSPO ligands described so far. 
 
EXPERIMENTAL SECTION 
Chemistry. Evaporation was performed in vacuo (rotary evaporator). Analytical TLC was carried 
out on Merck 0.2 mm precoated silica gel aluminum sheets (60 F-254). Silica gel 60 (230-400 
 mesh) was used for column chromatography. Melting points were determined using a Reichert 
Köfler hot-stage apparatus and are uncorrected. Routine nuclear magnetic resonance spectra were 
recorded in DMSO-d6 solution on a Varian Gemini 200 spectrometer operating at 200 MHz. The 
NMR spectra of tertiary amides show the presence of two different conformational isomers (ratio 
about 1:1) in equilibrium (see ref. n° 26,37 for details). Elemental analyses were performed by our 
analytical laboratory and agreed with theoretical values to within (0.4%). 
2-(p-Biphenyl-4-yl)indole 43 and 2-(naphth-2-yl)indole 44 are commercially available. 2-(4-
Methoxyphenyl)indole 36,39 2-(4-nitrophenyl)indole 37,26 2-(3-thienyl)-1H-indole 42,40 [2-(4-
nitrophenyl)indol-3-yl]glyoxylyl chloride 40,26 N,N-di-n-propyl-2-(4-nitrophenyl)indol-3-
ylglyoxylamide 7d,26 N,N-di-n-butyl-2-(4-nitrophenyl)indol-3-ylglyoxylamide 7e,26 N,N-di-n-
hexyl-2-(4-nitrophenyl)indol-3-ylglyoxylamide 7f,26 were prepared in accordance with reported 
procedures. 
Methyl-4-(1H-indol-2-yl)benzoate 38. 1 g of polyphosphoric acid (PPA) was added to a mixture 
of phenylhydrazine hydrochloride (0.541 g, 5.0 mmol) and methyl 4-acetylbenzoate (0.891 g, 5.0 
mmol). The reaction was maintained at 60 °C for 4 h and then poured into ice (ca 100 g). The 
precipitated solid was collected by filtration and purified by recrystallization from toluene (30 mL). 
Yield: 78%; mp 204-207 °C, lit. ref. n° 41 mp 206.3-207.5 °C. 
General procedure for the synthesis of [2-(4-substituted-phenyl)indol-3-yl]glyoxylyl chloride 
derivatives 39, 41, and (2-arylindol-3-yl)glyoxylyl chloride derivatives 45-47. Oxalyl chloride 
(8.0 mmol) was added dropwise at 0 °C to a well-stirred mixture of the appropriate indole 36, 38, 
42-44 (4.0 mmol) in freshly distilled diethyl ether (10 mL). The mixture was maintained at room 
temperature for 2-24 h (TLC analysis). The precipitate formed was collected and washed with 
portions of diethyl ether (20 mL) to give the desired glyoxylyl chlorides, which were dried over 
P2O5 in vacuo and directly used in the subsequent reaction. All glyoxylyl chloride derivatives, were 
characterized by conversion into their corresponding ethyl esters. 
2-(4-Methoxyphenyl)indol-3-ylglyoxylyl chloride (39). Yield: 72% 
 Ethyl [2-(4-methoxyphenyl)-1H-indol-3-yl](oxo)acetate 39a. Yield: 70%; mp 194-196 °C. 1H-
NMR (DMSO-d6, ppm): 0.99 (t, J = 7.2 Hz, 3H, CH2CH3); 3.68 (q, J = 7.2 Hz, 2H, CH2CH3); 3.85 
(s, 3H, OCH3); 7.12 (d, J = 6.8 Hz, 2H, 3'-H, 5'-H); 7.26-7.33 (m, 2H, Ar-H); 7.49-7.52 (m, 3H, Ar-
H); 8.12-8.15 (m, 1H, 4-H); 12.52 (bs, 1H, NH, exch. with D2O). Anal. Calcd for C19H17NO4: C, 
70.58; H, 5.30; N, 4.33. Found: C, 70.45; H, 5.17; N, 4.27. 
Methyl 4-{3-[chloro(oxo)acetyl]-1H-indol-2-yl} benzoate (41). Yield: 80% 
Methyl 4-{3-[ethoxy(oxo)acetyl]-1H-indol-2-yl}benzoate 41a. Yield: 70%; mp 152-154 °C. 1H-
NMR (DMSO-d6, ppm): 0.97 (t, J = 7.2 Hz, 3H, CH2CH3); 3.63 (q, J = 7.2 Hz, 2H, CH2CH3); 3.92 
(s, 3H, OCH3); 7.32-7.36 (m, 2H, Ar-H); 7.54-7.57 (m, 1H, Ar-H); 7.74 (d, J = 8.4 Hz, 2H, 2'-H, 6'-
H); 8.11-8.16 (m, 3H, Ar-H); 12.80 (bs, 1H, NH, exch. with D2O). Anal. Calcd for C20H17NO5: C, 
68.37; H, 4.88; N, 3.99. Found: C, 68.51; H, 4.71; N, 4.05. 
Oxo[2-(3-thienyl)-1H-indol-3-yl]acetyl chloride (45). Yield: 65% 
Ethyl oxo[2-(3-thienyl)-1H-indol-3-yl]acetate 45a. Yield: 72%; mp 168-170 °C. 1H-NMR 
(DMSO-d6, ppm): 1.06 (t, J = 7.2 Hz, 3H, CH2CH3); 3.82 (q, J = 7.2 Hz, 2H, CH2CH3); 7.28-7.33 
(m, 2H, Ar-H); 7.37-7.40 (m, 1H, Ar-H); 7.48-7.51 (m, 1H, Ar-H); 7.77-7.79 (m, 1H, Ar-H); 7.93-
7.94 (m, 1H, Ar-H); 8.07-8.09 (m, 1H, 4-H); 12.59 (bs, 1H, NH, exch. with D2O). Anal. Calcd for 
C16H13NO3S: C, 64.20; H, 4.38; N, 4.68. Found: C, 64.08; H, 4.47; N, 4.75. 
(2-Biphenyl-4-yl-1H-indol-3-yl)(oxo)acetyl chloride (46). Yield: 80% 
Ethyl (2-biphenyl-4-yl-1H-indol-3-yl)(oxo)acetate 46a. Yield: 90%; mp 145-147 °C. 1H-NMR 
(DMSO-d6, ppm): 0.98 (t, J = 7.2 Hz, 3H, CH2CH3); 3.67 (q, J = 7.2 Hz, 2H, CH2CH3); 7.31-7.36 
(m, 2H, Ar-H); 7.42-7.46 (m, 1H, Ar-H); 7.52-7.55 (m, 3H, Ar-H); 7.67 (d, J = 8.2 Hz, 2H, 3'-H, 5'-
H); 7.76-7.78 (m, 2H, Ar-H); 7.88 (d, J = 8.2 Hz, 2H, 2'-H, 6'-H); 8.16-8.18 (m, 1H, 4-H); 12.70 
(bs, 1H, NH, exch. with D2O). Anal. Calcd for C24H19NO3: C, 78.03; H, 5.18; N, 3.79. Found: C, 
78.19; H, 5.33; N, 3.61. 
[2-(2-Naphthyl)-1H-indol-3-yl](oxo)acetyl chloride (47). Yield: 82% 
Ethyl [2-(2-naphthyl)-1H-indol-3-yl](oxo)acetate 47a. Yield: 79%; mp 143-145 °C. 1H-NMR 
(DMSO-d6, ppm): 0.79 (t, J = 7.2 Hz, 3H, CH2CH3); 3.34 (q, J = 7.2 Hz, 2H, CH2CH3); 7.32-7.38 
 (m, 2H, Ar-H); 7.56-7.58 (m, 1H, Ar-H); 7.64-7.66 (m, 2H, Ar-H); 7.70-7.72 (m, 1H, Ar-H); 8.04-
8.06 (m, 2H, Ar-H); 8.09-8.14 (m, 2H, Ar-H); 8.19-8.21 (m, 1H, 4-H); 12.76 (bs, 1H, NH, exch. 
with D2O). Anal. Calcd for C22H17NO3: C, 76.95; H, 4.99; N, 4.08. Found: C, 77.10; H, 4.83; N, 
4.17. 
General procedure for the synthesis of N,N-dialkyl-[2-(4-substituted-phenyl)indol-3-
yl]glyoxylamide derivatives 17-22, and N,N-dialkyl-[(2-arylindol)-3-yl]glyoxylamide 
derivatives 23-35. A solution of the appropriate amine (2.0 mmol) in 5 mL of dry toluene was 
added dropwise to a stirred suspension, cooled at 0 °C, of the glyoxylyl chlorides 39-41, 45-47 (2.0 
mmol) in 50 mL of the same solvent, followed by the addition of triethylamine (2.0 mmol). The 
reaction mixture was left under stirring for 2-24 h at room temperature (TLC analysis), and then 
filtered. The collected precipitate was triturated with a 5% NaHCO3 aqueous solution (10 mL), 
washed with water (10 mL), and collected again to give a first portion of crude product. The toluene 
was removed under reduced pressure, and the oily residue dissolved with CHCl3 (20-30 mL). The 
organic solution was washed with diluted HCl (10 mL), a 5% NaHCO3 aqueous solution (10 mL) 
and water (10 mL), dried (MgSO4), and evaporated to dryness to yield an additional amount of 
crude products, which were finally purified by flash chromatography (CHCl3 as eluent). 
2-[2-(4-Methoxyphenyl)-1H-indol-3-yl]-2-oxo-N,N-dipropylacetamide (17). Yield: 72%; mp 
121-123 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.68, 0.76 (2t, J = 7.2 
Hz, 6H, 2(CH2)2CH3); 1.21-1.26, 1.39-1.47 (2m, 4H, 2CH2CH2CH3); 2.93-3.06 (m, 4H, 2NCH2); 
3.83 (s, 3H, OCH3); 7.06 (d, J = 8.8 Hz, 2H, 3'-H, 5'-H); 7.18-7.30 (m, 2H, Ar-H); 7.44-7.56 (m, 
3H, Ar-H); 7.99-8.04 (m, 1H, 4-H); 12.34 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, 
ppm, mixture of conformational isomers): 11.38; 11.76; 20.55; 21.71; 46.03; 49.76; 55.82; 109.84; 
112.39; 113.94; 121.20; 122.71; 123.44; 123.66; 127.35; 131.81; 136.14; 147.75; 160.90; 168.18; 
187.62. Anal. Calcd for C23H26N2O3: C, 72.99; H, 6.92; N, 7.40. Found: C, 73.12; H, 6.80; N, 7.33. 
N,N-Dibutyl-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]-2-oxoacetamide (18). Yield: 75%; mp 119-
121 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.72, 0.84 (2t, J = 7.0 Hz, 
 6H, 2(CH2)3CH3); 1.02-1.13 (m, 6H, Aliph-H); 1.35-1.43 (m, 2H, Aliph-H); 2.98-3.07 (m, 4H, 
2NCH2); 3.83 (s, 3H, OCH3); 7.06 (d, J = 8.8 Hz, 2H, 3'-H, 5'-H); 7.20-7.28 (m, 2H, Ar-H); 7.44-
7.55 (m, 3H, Ar-H); 8.03-8.06 (m, 1H, 4-H); 12.53 (bs, 1H, NH, exch. with D2O). 
13C-NMR 
(DMSO-d6, ppm, mixture of conformational isomers): 13.89; 14.11; 19.70; 20.23; 29.28; 30.40; 
43.89; 47.55; 55.77; 109.87; 112.37; 113.91; 121.24; 122.70; 123.38; 123.67; 127.38; 131.86; 
136.17; 147.79; 160.88; 168.00; 187.70. Anal. Calcd for C25H30N2O3: C, 73.86; H, 7.44; N, 6.89. 
Found: C, 73.72 ; H, 7.51; N, 6.99. 
N,N-Dihexyl-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]-2-oxoacetamide (19). Yield: 65%; oil. 1H-
NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.73-1.36 (m, 22H, Aliph-H); 2.98-
3.05 (m, 4H, 2NCH2); 3.81 (s, 3H, OCH3); 7.05 (d, J = 6.8 Hz, 2H, 3'-H, 5'-H); 7.20-7.25 (m, 2H, 
Ar-H); 7.43-7.54 (m, 3H, Ar-H); 8.01-8.04 (m, 1H, 4-H); 12.33 (bs, 1H, NH, exch. with D2O). 
13C-
NMR (DMSO-d6, ppm, mixture of conformational isomers): 14.20; 14.36; 22.26; 22.47; 26.02; 
26.64; 27.09; 28.19; 31.08; 31.46; 43.57; 47.79; 55.77; 109.87; 112.38; 113.90; 121.26; 121.65; 
122.32; 123.35; 127.35; 131.87; 136.19; 148.12; 159.34; 168.00; 187.91. Anal. Calcd for 
C29H38N2O3: C, 75.29; H, 8.28; N, 6.06. Found: C, 75.13; H, 8.21; N, 6.00. 
Methyl 4-{3-[(dipropylamino)(oxo)acetyl]-1H-indol-2-yl}benzoate (20). Yield: 65%; mp 139-
141 °C; 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.66-0.77 (m, 6H, 
2(CH2)2CH3); 1.20-1.27, 1.45-1.49 (2m, 4H, 2CH2CH2CH3); 2.93-3.10 (m, 4H, 2NCH2); 3.92 (s, 
3H, OCH3); 7.27-7.31 (m, 2H, Ar-H); 7.50-7.54 (m, 1H, Ar-H); 7.74 (d, J = 8.0 Hz, 2H, 2'-H, 6'-H); 
8.02-8.09 (m, 3H, 4-H); 12.64 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture 
of conformational isomers): 11.38; 11.71; 20.46; 21.77; 46.03; 49.77; 52.83; 110.49; 112.79; 
121.27; 123.02; 124.10; 127.13; 129.10; 130.74; 130.82; 136.12; 136.51; 146.10; 166.37; 167.95; 
187.37. Anal. Calcd for C24H26N2O4: C, 70.92; H, 6.45; N, 6.89. Found: C, 7.79; H, 6.53; N, 6.95. 
Methyl 4-{3-[(dibutylamino)(oxo)acetyl]-1H-indol-2-yl}benzoate (21). Yield: 71%; mp 119-121 
°C; 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.69-0.80 (m, 6H, 
2(CH2)3CH3); 1.00-1.15 (m, 4H, 2(CH2)2CH2CH3); 1.25-1.41 (m, 4H, 2CH2CH2CH2CH3); 2.95-
 3.09 (m, 4H, 2NCH2); 3.89 (s, 3H, OCH3); 7.25-7.30 (m, 2H, Ar-H); 7.48-7.52 (m, 1H, Ar-H); 7.72 
(d, J = 8.0 Hz, 2H, 2'-H, 6'-H); 8.04-8.09 (m, 3H, 4-H); 12.59 (bs, 1H, NH, exch. with D2O). 
13C-
NMR (DMSO-d6, ppm, mixture of conformational isomers): 13.90; 14.01; 19.70; 20.16; 29.12; 
30.41; 43.93; 47.55; 52.78; 110.63; 112.70; 121.42; 123.06; 124.17; 127.17; 129.17; 130.81; 
130.90; 136.01; 136.42; 146.08; 166.32; 167.69; 187.56. Anal. Calcd for C26H30N2O4: C, 71.87; H, 
6.96; N, 6.45. Found: C, 71.72; H, 6.89; N, 6.54. 
Methyl 4-{3-[(dihexylamino)(oxo)acetyl]-1H-indol-2-yl}benzoate (22). Yield: 65%; oil. 1H-NMR 
(DMSO-d6, ppm, mixture of conformational isomers): 0.66-1.46 (m, 22H, Aliph-H); 2.85-2.97 (m, 
4H, 2NCH2); 3.81 (s, 3H, OCH3); 7.18-7.21 (m, 2H, Ar-H); 7.39-7.42 (m, 1H); 7.64 (d, J = 7.8 Hz, 
2H, 2'-H, 6'-H); 7.96-8.00 (m, 3H, Ar-H); 12.53 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-
d6, ppm, mixture of conformational isomers): 14.19; 14.33; 22.28; 22.47; 26.03; 26.60; 26.87; 
28.14; 31.09; 31.45; 44.18; 47.76; 52.76; 110.61; 112.67; 121.43; 123.04; 124.17; 127.14; 129.16; 
130.79; 130.91; 135.96; 136.39; 145.98; 166.29; 167.67; 187.61. Anal. Calcd for C30H38N2O4: C, 
73.44; H, 7.81; N, 5.71. Found: C, 73.56; H, 7.72; N, 5.65. 
2-Oxo-N,N-dipropyl-2-[2-(3-thienyl)-1H-indol-3-yl]acetamide (23). Yield: 78%; mp 69-71 °C. 
1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.65, 0.71 (2t, J = 7.2 Hz, 6H, 
2(CH2)2CH3); 1.30-1.50 (m, 4H, 2CH2CH2CH3); 3.00-3.14 (m, 4H, 2NCH2); 7.21-7.27 (m, 2H, Ar-
H); 7.46-7.50 (m, 2H, Ar-H); 7.69-7.73 (m, 1H, Ar-H); 7.89-7.93 (m, 1H, 4-H); 8.13 (s, 1H, 2'-H); 
12.45 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
isomers): 11.36; 11.81; 20.64; 21.73; 46.09; 49.72; 109.87; 112.48; 120.92; 122.75; 123.85; 126.53; 
127.05; 128.74; 129.23; 131.42; 136.05; 142.02; 168.49; 187.32. Anal. Calcd for C20H22N2O2S: C, 
67.77; H, 6.26; N, 7.90. Found: C, 67.91; H, 6.19; N, 7.95. 
N,N-Dibutyl-2-oxo-2-[2-(3-thienyl)-1H-indol-3-yl]acetamide (24). Yield: 79%; mp 119-121 °C. 
1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.66-1.09 (m, 10H, Aliph-H); 1.22-
1.35 (m, 4H, 2CH2CH2CH2CH3); 3.00-3.32 (m, 4H, 2NCH2); 7.16-7.30 (m, 2H, Ar-H); 7.45-7.49 
(m, 2H, Ar-H); 7.68-7.72 (m, 1H, Ar-H); 7.88-7.92 (m, 1H, 4-H); 8.11 (s, 1H, 2'-H); 12.43 (bs, 1H, 
 NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational isomers): 13.82; 
14.21; 19.66; 20.24; 29.41; 30.44; 43.98; 47.59; 109.85; 112.46; 120.93; 122.73; 123.86; 126.55; 
127.04; 128.79; 129.23; 131.38; 136.04; 141.98; 168.37; 187.37. Anal. Calcd for C22H26N2O2S: C, 
69.08; H, 6.85; N, 7.32. Found: C, 69.19; H, 6.76; N, 7.39. 
N,N-Dihexyl-2-oxo-2-[2-(3-thienyl)-1H-indol-3-yl]acetamide (25). Yield: 82%; oil. 1H-NMR 
(DMSO-d6, ppm, mixture of conformational isomers, mixture of conformational isomers): 0.66-
1.12 (m, 14H, Aliph-H); 1.26-1.39 (m, 8H, Aliph-H); 3.00-3.20 (m, 4H, 2NCH2); 7.18-7.29 (m, 2H, 
Ar-H); 7.45-7.51 (m, 2H, Ar-H); 7.68-7.72 (m, 1H, Ar-H); 7.87-7.93 (m, 1H, 4-H); 8.14 (s, 1H, 2'-
H); 12.44 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
isomers): 14.17; 14.37; 22.21; 22.50; 25.98; 26.63; 27.22; 28.14; 31.00; 31.48; 44.23; 47.48; 
109.76; 112.49; 120.88; 122.67; 123.82; 126.50; 127.02; 128.81; 129.21; 131.40; 136.07; 141.90; 
168.43; 187.32. Anal. Calcd for C26H34N2O2S: C, 71.19; H, 7.81; N, 6.39. Found: C, 71.05; H, 7.89; 
N, 6.32. 
2-(2-Biphenyl-4-yl-1H-indol-3-yl)-2-oxo-N,N-dipropylacetamide (26). Yield: 70%; mp 155-157 
°C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.67-0.73 (m, 6H, 
2(CH2)2CH3); 1.15-1.20, 1.45-1.51 (2m, 4H, 2CH2CH2CH3); 2.92-3.10 (m, 4H, 2NCH2); 7.29-7.32 
(m, 2H, Ar-H); 7.51-7.55 (m, 4H, Ar-H); 7.68-7.81 (m, 6H, Ar-H); 8.06-8.08 (m, 1H, 4-H), 12.52 
(bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational isomers): 
11.40; 11.77; 20.93; 21.71; 46.01; 49.75; 110.29; 112.55; 121.31; 122.90; 123.91; 126.68; 127.24; 
127.28; 128.39; 129.53; 130.33; 130.99; 136.26; 139.94; 141.80; 147.31; 168.02; 187.68. Anal. 
Calcd for C28H28N2O2: C, 79.22; H, 6.65; N, 6.60. Found: C, 79.56; H, 6.81; N, 6.44. 
2-(2-Biphenyl-4-yl-1H-indol-3-yl)-N,N-dibutyl-2-oxoacetamide (27). Yield: 67%; mp 153-155 
°C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.71-0.78 (m, 6H, 
2(CH2)3CH3); 1.07-1.15 (m, 6H, Aliph-H); 1.41-1.44 (m, 2H, Aliph-H); 2.98-3.11 (m, 4H, 2NCH2); 
7.27-7.34 (m, 2H, Ar-H); 7.42-7.57 (m, 4H, Ar-H); 7.66-7.86 (m, 6H, Ar-H); 8.07-8.11 (m, 1H, 4-
H); 12.51 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
 isomers): 13.93; 13.99; 19.72; 20.18; 29.08; 30.45; 43.95; 47.65; 110.27; 112.55; 121.33; 122.87; 
123.90; 126.58; 127.18; 127.34; 128.40; 129.50; 130.33; 131.02; 136.33; 139.77; 141.64; 147.31; 
167.93; 187.72. Anal. Calcd for C30H32N2O2: C, 79.61; H, 7.13; N, 6.19. Found: C, 79.91; H, 7.27; 
N, 5.92. 
2-(2-Biphenyl-4-yl-1H-indol-3-yl)-N,N-dihexyl-2-oxoacetamide (28). Yield: 65%; mp 50-52 °C. 
1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.72-0.75 (m, 6H, 2(CH2)5CH3); 
1.07-1.14 (m, 14H, Aliph-H); 1.41-1.44 (m, 2H, Aliph-H); 2.92-3.08 (m, 4H, 2NCH2); 7.25-7.34 
(m, 2H, Ar-H); 7.42-7.52 (m, 4H, Ar-H); 7.66-7.85 (m, 6H, Ar-H); 8.07-8.10 (m, 1H, 4-H), 12.51 
(bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational isomers): 
14.21; 14.24; 22.31; 22.48; 26.07; 26.69; 28.18; 31.13; 31.38; 39.40; 44.20; 47.84; 110.30; 112.51; 
121.40; 122.86; 123.91; 126.55; 127.15; 127.33; 128.38; 129.47; 130.29; 131.04; 136.30; 139.70; 
141.61; 147.26; 167.88; 187.77. Anal. Calcd for C34H40N2O2: C, 80.28; H, 7.93; N, 5.51. Found: C, 
80.29; H, 8.15; N, 5.40. 
2-[2-(2-Naphthyl)-1H-indol-3-yl]-2-oxo-N,N-dipropylacetamide (29). Yield: 60%; mp 171-172 
°C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.51, 0.71 (2t, J = 7.2 Hz, 6H, 
2(CH2)2CH3); 0.86-0.98, 1.41-1.52 (2m, 4H, 2CH2CH2CH3); 2.79, 3.08 (2t, J = 7.0 Hz, 4H, 
2NCH2); 7.28-7.32 (m, 2H, Ar-H); 7.51-7.56 (m, 1H, Ar-H); 7.64-7.72 (m, 3H, Ar-H); 8.00-8.09 
(m, 4H, Ar-H); 8.17 (s, 1H, 1'-H); 12.60 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, 
mixture of conformational isomers): 11.39; 11.56; 20.18; 21.75; 45.94; 49.81; 110.46; 112.57; 
121.33; 122.92; 123.94; 127.15; 127.29; 127.57; 127.60; 127.82; 128.07; 128.76; 128.85; 130.06; 
132.65; 133.65; 136.35; 147.62; 168.00; 187.68. Anal. Calcd for C26H26N2O2: C, 78.36; H, 6.58; N, 
7.03. Found: C, 78.49; H, 6.63; N, 6.95. 
N,N-Dibutyl-2-[2-(2-naphthyl)-1H-indol-3-yl]-2-oxoacetamide (30). Yield: 79%; mp 98-100 °C. 
1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.54, 075 (2t, J = 7.2 Hz, 6H, 
2(CH2)3CH3); 0.63-0.70, 0.83-0.90 (2m, 4H, 2(CH2)2CH2CH3); 1.09-1.14, 1.37-1.42 (2m, 4H, 
2CH2CH2CH2CH3); 2.79, 3.09 (2t, J = 7.6 Hz, 4H, 2NCH2); 7.27-7.35 (m, 2H, Ar-H); 7.50-7.53 (m, 
 1H, Ar-H); 7.60-7.70 (m, 3H, Ar-H); 8.00-8.05 (m, 3H, Ar-H); 8.11-8.14 (m, 1H, 4-H); 8.16 (s, 1H, 
1'-H); 12.56 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
isomers): 13.89; 13.94; 19.72; 19.96; 28.78; 30.43; 43.81; 47.59; 110.55; 112.53; 121.43; 122.93; 
123.96; 127.16; 127.34; 127.57; 127.59; 127.87; 128.14; 128.77; 130.20; 132.67; 133.68; 136.36; 
147.66; 167.80; 187.83. Anal. Calcd for C28H30N2O2: C, 78.84; H, 7.09; N, 6.57. Found: C, 78.71; 
H, 7.05; N, 6.49. 
N,N-Dihexyl-2-[2-(2-naphthyl)-1H-indol-3-yl]-2-oxoacetamide (31). Yield: 88%; oil. 1H-NMR 
(DMSO-d6, ppm, mixture of conformational isomers): 0.70-0.88 (m, 10H, Aliph-H); 1.08-1.41 (m, 
12H, Aliph-H); 2.82, 3.10 (2t, J = 7.6 Hz, 4H, 2NCH2); 7.27-7.35 (m, 2H, Ar-H); 7.51-7.59 (m, 1H, 
Ar-H); 7.61-7.71 (m, 3H, Ar-H); 8.00-8.04 (m, 3H, Ar-H); 8.10-8.12 (m, 1H, 4-H); 8.16 (s, 1H, 1'-
H); 12.57 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
isomers): 14.22; 14.31; 22.31; 22.36; 26.07; 26.41; 26.58; 28.18; 31.14; 31.19; 44.08; 47.82; 
110.50; 112.54; 121.42; 122.89; 123.94; 127.14; 127.33; 127.57; 127.85; 128.12; 128.76; 130.20; 
132.66; 133.66; 136.38; 147.61; 167.80; 187.82. Anal. Calcd for C32H38N2O2: C, 79.63; H, 7.94; N, 
5.80. Found: C, 79.75; H, 7.97; N, 5.86. 
N-Butyl-N-methyl-2-[2-(2-naphthyl)-1H-indol-3-yl]-2-oxoacetamide (32). Yield: 70%; mp 74-
76 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.56-0.92 (m, 5H, 
(CH2)2CH2CH3); 1.12-1.56 (m, 2H, CH2CH2CH2CH3); 2.24, 2.82 (2s, 3H, NCH3); 2.67, 3.13 (2t, J 
=7.2 Hz, 2H, NCH2); 7.29-7.36 (m, 2H, Ar-H); 7.51-7.55 (m, 1H, Ar-H); 7.61-7.69 (m, 3H, Ar-H); 
8.01-8.05 (m, 3H, Ar-H); 8.15 (s, 1H, 1'-H); 8.17-8.19 (m, 1H, 4-H); 12.62 (bs, 1H, NH, exch. with 
D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational isomers): 13.89; 13.99; 19.60; 19.74; 
28.08; 29.93; 31.04; 35.02; 45.49; 49.44; 110.57; 110.59; 112.56; 121.47; 121.51; 123.04; 124.02; 
124.05; 127.18; 127.20; 127.27; 127.39; 127.46; 127.50; 127.63; 127.65; 127.86; 128.14; 128.66; 
128.68; 128.74; 128.75; 129.92; 130.12; 132.53; 132.62; 133.56; 133.69; 136.33; 136.39; 147.83; 
148.01; 167.48; 167.74; 187.78; 188.03. Anal. Calcd for C25H24N2O2: C, 78.10; H, 6.29; N, 7.29. 
Found: C, 78.23; H, 6.21; N, 7.32. 
 N-Methyl-2-[2-(2-naphthyl)-1H-indol-3-yl]-2-oxo-N-pentylacetamide (33). Yield: 65%; mp 153-
155 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.70-1.00 (m, 7H, Aliph-
H); 1.08-1.42 (m, 2H, CH2CH2(CH2)2CH3); 2.25, 2.82 (2s, 3H, NCH3); 2.66, 3.12 (2t, J = 7.2 Hz, 
2H, NCH2); 7.28-7.36 (m, 2H, Ar-H); 7.51-7.55 (m, 1H, Ar-H); 7.64-7.69 (m, 3H, Ar-H); 8.01-8.05 
(m, 3H, Ar-H); 8.15 (s, 1H, 1'-H); 8.16-8.18 (m, 1H, 4-H); 12.60 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational isomers): 14.28; 14.23; 22.06; 22.14; 25.60; 
27.42; 28.47; 28.72; 31.03; 35.04; 45.75; 49.65; 110.56; 110.59; 112.56; 121.46; 121.50; 123.04; 
124.02; 124.05; 127.18; 127.26; 127.39; 127.44; 127.50; 127.61; 127.65; 127.86; 128.13; 128.67; 
128.69; 128.74; 129.91; 130.12; 132.53; 132.62; 133.56; 133.67; 136.33; 136.39; 147.80; 148.01; 
167.47; 167.76; 187.76; 188.01. Anal. Calcd for C26H26N2O2: C, 78.36; H, 6.58; N, 7.03. Found: C, 
78.49; H, 6.62; N, 6.97. 
N-Butyl-N-ethyl-2-[2-(2-naphthyl)-1H-indol-3-yl]-2-oxoacetamide (34). Yield: 63%; mp 179-
181 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.53-1.04 (m, 10H, Aliph-
H); 2.81-2.87 (m, 2H, Aliph-H); 3.20-3.33 (m, 2H, Aliph-H); 7.27-7.32 (m, 2H, Ar-H); 7.51-7.53 
(m, 1H, Ar-H); 7.61-7.70 (m, 3H, Ar-H); 8.00-8.04 (m, 3H, Ar-H); 8.12-8.14 (m, 1H, 4-H); 8.15 (s 
1H, 1'-H); 12.58 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of 
conformational isomers): 12.28; 13.91; 13.96; 14.02; 19.74; 19.95; 28.81; 30.54; 38.84; 42.58; 
43.26; 47.47; 121.34; 121.44; 122.90; 123.92; 127.14; 127.16; 127.39; 127.45; 127.58; 127.80; 
127.86; 128.10; 128.14; 128.75; 128.77; 128.89; 128.93; 130.10; 130.20; 132.64; 132.67; 133.61; 
133.67; 136.52; 147.80; 147.98; 167.70; 187.66; 187.83. Anal. Calcd for C26H26N2O2: C, 78.36; H, 
6.58; N, 7.03. Found: C, 78.49; H, 6.49; N, 7.07. 
N-Benzyl-N-ethyl-2-[2-(2-naphthyl)-1H-indol-3-yl]-2-oxoacetamide (35). Yield: 70%; mp 83-85 
°C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.26, 0.91 (2t, J = 7.0 Hz, 3H, 
CH3); 2.73, 3.22 (2q, J = 7.0 Hz, 2H, NCH2CH3); 4.17, 4.41 (2s, 2H, NCH2C6H5); 7.00-7.04 (m, 
2H, Ar-H); 7.18-7.35 (m, 5H, Ar-H); 7.53-7.77 (m, 4H, Ar-H); 7.97-8.06 (m, 4H, Ar-H); 8.23-8.25 
(m, 1H, 4-H); 12.65 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of 
 conformational isomers): 11.47; 13.96; 38.40; 42.85; 46.73; 50.96; 110.02; 110.80; 112.62; 112.67; 
121.22; 121.46; 122.96; 123.08; 123.98; 123.98; 124.08; 127.25; 127.38; 127.56; 127.59; 127.71; 
127.83; 127.96; 128.14; 128.21; 128.27; 128.54; 128.74; 128.80; 128.83; 128.85; 130.07; 130.20; 
132.66; 132.69; 133.67; 133.69; 136.42; 136.76; 137.36; 147.72; 148.17; 167.80; 168.39; 187.29; 
187.68. Anal. Calcd for C29H24N2O2: C, 80.53; H, 5.59; N, 6.48. Found: C, 80.41; H, 5.49; N, 6.57. 
General procedure for the synthesis of N,N-dialkyl-2-(4-hydroxyphenyl)indol-3-
ylglyoxylamide derivatives 8-10. A stirred suspension of the appropriate derivative 17-19 (0.5 
mmol) in 10 mL of dry dichloromethane was cooled to -10 °C and an excess (0.2 mL) of BBr3 was 
added dropwise. The mixture was left under stirring for 30 min. at -10 °C, and subsequently at room 
temperature for 1h under nitrogen atmosphere. Finally, the solution was cooled again, and methanol 
(5 mL) was added to hydrolyze the excess of BBr3. The solvent was evaporated at reduced pressure, 
and the solid precipitate was washed several times with methanol (3 x 5 mL). The residues obtained 
were purified by crystallization from toluene (compound 8, 20 mL) or by flash chromatography 
(compounds 9 and 10, ethyl acetate-petroleum ether 60-80 °C in varying v/v ratios as eluting 
system). 
2-[2-(4-Hydroxyphenyl)-1H-indol-3-yl]-2-oxo-N,N-dipropylacetamide (8). Yield: 59%; mp 210-
212 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.64-0.82 (m, 6H, 
2(CH2)2CH3); 1.27-1.46 (m, 4H, 2CH2CH2CH3); 2.95-3.02 (m, 4H, 2NCH2); 6.86 (d, J = 8.4 Hz, 
2H, 3'-H, 5'-H); 7.17-7.25 (m, 2H, Ar-H); 7.40-7.44 (m, 3H, Ar-H); 8.00-8.03 (m, 1H, 4-H); 9.90 
(bs, 1H, OH, exch. with D2O); 12.27 (bs, 1H, NH, exch. with D2O). 
13C NMR (DMSO-d6, ppm, 
mixture of conformational isomers): 11.39; 11.84; 20.58; 21.72; 46.10; 49.82; 109.60; 112.32; 
115.22; 121.15; 121.74; 122.63; 123.55; 127.40; 131.80; 136.08; 148.31; 159.32; 168.22; 187.64. 
Anal. Calcd for C22H24N2O3: C, 72.50; H, 6.64; N, 7.69. Found: C, 72.39; H, 6.59; N, 7.77. 
N,N-Dibutyl-2-[2-(4-hydroxyphenyl)-1H-indol-3-yl]-2-oxoacetamide (9). Yield: 68%; mp 250-
252 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.68-0.84 (m, 6H, 
2(CH2)3CH3); 1.02-1.35 (m, 8H, 2CH2(CH2)2CH3); 1.21-1.36, 2.96-2.99 (2m, 4H, 2NCH2); 6.83 (d, 
 J = 6.2 Hz, 2H, 3'-H, 5'-H); 7.19-7.21 (m, 2H, Ar-H); 7.37-7.40 (m, 3H, Ar-H); 7.98-8.00 (m, 1H, 
4-H); 9.84 (bs, 1H, OH, exch. with D2O); 12.22 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-
d6, ppm, mixture of conformational isomers): 13.99; 14.14; 19.75; 20.27; 29.50; 30.57; 44.07; 
47.93; 111.04; 111.38; 115.25; 119.50; 121.55; 123.29; 123.83; 126.45; 132.47; 137.17; 149.73; 
159.25; 167.54; 187.95. Anal. Calcd for C24H28N2O3: C, 73.44; H, 7.19; N, 7.14. Found: C, 73.59; 
H, 7.28; N, 7.26. 
N,N-Dihexyl-2-[2-(4-hydroxyphenyl)-1H-indol-3-yl]-2-oxoacetamide (10). Yield: 55%; oil. 1H-
NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.68-0.88 (m, 6H, 2(CH2)5CH3); 1.04-
1.23 (m, 16H, Aliph-H); 2.95-3.05 (m, 4H, 2NCH2); 6.85 (d, J = 8.4 Hz, 2H, 3'-H, 5'-H); 7.18-7.22 
(m, 2H, Ar-H); 7.38-7.45 (m, 3H, Ar-H); 7.97-8.00 (m, 1H, 4-H); 9.88 (bs, 1H, OH, exch. with 
D2O); 12.27 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
isomers): 14.13; 14.23; 22.30; 22.56; 26.07; 26.71; 27.19; 28.21; 31.12; 31.47; 44.28; 47.81; 
109.50; 112.24; 115.16; 121.20; 121.65; 122.54; 123.48; 127.37; 131.87; 136.06; 148.23; 159.34; 
168.01; 187.90. Anal. Calcd for C28H36N2O3: C, 74.97; H, 8.09; N, 6.24. Found: C, 74.85; H, 7.98; 
N, 6.30. 
General procedure for the synthesis of N,N-dialkyl-2-(4-aminophenyl)indol-3-
ylglyoxylamide derivatives 11-13. Pd/C 10% (0.05 g) was added to a suspension of the 
appropriate derivative 7d-f26 (0.65 mmol) in 150 mL of absolute ethanol. The mixture was 
hydrogenated under stirring at room temperature. Once hydrogen absorption ceased, the catalyst 
was filtered off and the solution was evaporated to dryness at reduced pressure. The crude products 
obtained were finally purified by recrystallization from toluene (20-30 mL).  
2-[2-(4-Aminophenyl)-1H-indol-3-yl]-2-oxo-N,N-dipropylacetamide (11). Yield: 62%; mp 197-
199 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.67, 0.81 (2t, J = 7.2 Hz, 
6H, 2(CH2)2CH3); 1.29-1.49 (m, 4H, 2CH2CH2CH3); 2.97-3.08 (m, 4H, 2NCH2); 5.57 (bs, 2H, 
NH2, exch. with D2O); 6.62 (d, J = 8.4 Hz, 2H, 3'-H, 5'-H); 7.17-7.43 (m, 5H, Ar-H); 7.92-7.97 (m, 
1H, 4-H); 12.09 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of 
 conformational isomers): 11.41; 11.89; 20.60; 21.67; 46.08; 49.77; 108.90; 112.14; 113.23; 117.84; 
120.93; 122.39; 123.25; 127.64; 131.29; 136.10; 149.30; 150.87; 168.50; 187.45. Anal. Calcd for 
C22H25N3O2: C, 72.70; H, 6.93; N, 11.56. Found: C, 72.82; H, 6.87; N, 11.62. 
2-[2-(4-Aminophenyl)-1H-indol-3-yl]-N,N-dibutyl-2-oxoacetamide (12). Yield: 61%; mp 225-
227 °C; 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.64, 0.87 (2t, J = 7.2 Hz, 
6H, 2(CH2)3CH3); 0.98-1.36 (m, 8H, 2CH2(CH2)2CH3); 3.00-3.06 (m, 4H, 2NCH2); 5.52 (bs, 2H, 
NH2, exch. with D2O); 6.61 (d, J = 8.4 Hz, 2H, 3'-H, 5'-H); 7.15-7.41 (m, 5H, Ar-H); 7.93-7.96 (m, 
1H, 4-H); 12.08 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of 
conformational isomers): 13.88; 14.23; 19.72; 20.28; 29.34; 30.38; 43.90; 47.56; 108.92; 112.11; 
113.22; 117.74; 120.97; 122.38; 123.27; 127.66; 131.35; 136.11; 149.33; 150.89; 168.34; 187.54. 
Anal. Calcd for C24H29N3O2: C, 73.63; H, 7.47; N, 10.73. Found: C, 73.52; H, 7.56; N, 10.79. 
2-[2-(4-Aminophenyl)-1H-indol-3-yl]-N,N-dihexyl-2-oxoacetamide (13). Yield: 68%; mp 147-
149 °C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.68-0.89 (m, 6H, 
2(CH2)3CH3); 0.93-1.24 (m, 16H, Aliph-H); 2.97-3.12 (m, 4H, 2NCH2); 5.58 (bs, 2H, NH2, exch. 
with D2O); 6.60 (d, J = 8.6 Hz, 2H, 3'-H, 5'-H); 7.16-7.41 (m, 5H, Ar-H); 7.90-7.93 (m, 1H, 4-H); 
12.08 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
isomers): 14.20; 14.37; 22.26; 22.54; 26.05; 26.71; 27.19; 28.13; 31.08; 31.45; 44.21; 47.83; 
108.82; 112.12; 113.33; 117.94; 120.90; 122.33; 123.23; 127.61; 131.35; 136.13; 149.22; 150.64; 
168.42; 187.43. Anal. Calcd for C28H37N3O2: C, 75.13; H, 8.33; N, 9.39. Found: C, 75.02; H, 8.39; 
N, 9.28. 
General procedure for the synthesis of N,N-dialkyl-2-(4-carboxyphenyl)indol-3-
ylglyoxylamide derivatives 14-16. Lithium hydroxide monohydrate (0.3 mmol) was added to a 
suspension of the appropriate ester derivative 20-23 (0.5 mmol) in 20 mL of a MeOH/H2O (3:1) 
solution. The mixture was stirred under reflux at 80 °C overnight. The solid precipitate was 
eliminated through vacuum filtration, and the solution was acidified with 10% HCl to pH 5. The 
acid precipitated was collected by filtration and did not need any further purification. 
 4-{3-[(Dipropylamino)(oxo)acetyl]-1H-indol-2-yl}benzoic acid (14). Yield: 85%; mp 292-294 
°C. 1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.64-0.75 (m, 6H, 
2(CH2)2CH3); 1.15-1.26, 1.43-1.47 (2m, 4H, 2CH2CH2CH3); 2.91-3.11 (m, 4H, 2NCH2); 7.27-7.31 
(m, 2H, Ar-H); 7.49-7.51 (m, 1H, Ar-H); 8.10 (d, J = 7.8 Hz, 2H, 3'-H, 5'-H); 8.03-8.07 (m, 3H, Ar-
H); 12.63 (bs, 1H, NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational 
isomers): 11.38; 11.73; 20.43; 21.76; 46.03; 49.78; 110.48; 112.69; 121.32; 123.05; 124.12; 127.09; 
129.24; 130.64; 132.10; 135.51; 136.31; 146.27; 167.40; 167.89; 187.50. Anal. Calcd for 
C23H24N2O4: C, 70.39; H, 6.16; N, 7.14. Found: C, 70.22; H, 6.25; N, 7.18. 
4-{3-[(Dibutylamino)(oxo)acetyl]-1H-indol-2-yl}benzoic acid (15). Yield: 87%; mp 148-150 °C. 
1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.68-0.81 (m, 6H, 2(CH2)3CH3); 
1.03-1.40 (m, 8H, 2CH2(CH2)2CH3); 2.93-3.04 (m, 4H, 2NCH2); 7.25-7.28 (m, 2H, Ar-H); 7.46-
7.50 (m, 1H, Ar-H); 7.68 (d, J = 6.8 Hz, 2H, 3'-H, 5'-H); 8.00-8.08 (m, 3H, Ar-H); 12.56 (bs, 1H, 
NH, exch. with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational isomers): 13.91; 
14.07; 19.70; 20.17; 29.09; 30.42; 43.93; 47.57; 110.57; 112.65; 121.44; 123.05; 124.14; 127.17; 
129.31; 130.71; 132.11; 135.48; 136.33; 146.32; 167.37; 167.68; 187.64. Anal. Calcd for 
C25H28N2O4: C, 71.41; H, 6.71; N, 6.66. Found: C, 71.27; H, 6.79; N, 6.57. 
4-{3-[(Dihexylamino)(oxo)acetyl]-1H-indol-2-yl}benzoic acid (16). Yield: 79%; mp 242-244 °C. 
1H-NMR (DMSO-d6, ppm, mixture of conformational isomers): 0.73-0.84 (m, 6H, 2(CH2)5CH3); 
1.00-1.38 (m, 16H, Aliph-H); 2.93-3.03 (m, 4H, 2NCH2); 7.24-7.27 (m, 2H, Ar-H); 7.46-7.50 (m, 
1H, Ar-H); 7.68 (d, J = 7.8 Hz, 2H, 3'-H, 5'-H); 8.00-8.05 (m, 3H, Ar-H); 12.56 (bs, 1H, NH, exch. 
with D2O). 
13C-NMR (DMSO-d6, ppm, mixture of conformational isomers): 14.20; 14.32; 22.29; 
22.48; 26.04; 26.59; 26.88; 28.17; 31.10; 31.38; 44.19; 47.80; 110.53; 112.64; 121.42; 123.01; 
124.12; 127.15; 129.28; 130.70; 132.09; 135.47; 136.35; 146.25; 167.33; 167.70; 187.63. Anal. 
Calcd for C29H36N2O4: C, 73.08; H, 7.61; N, 5.88. Found: C, 72.95; H, 7.71; N, 5.96. 
Biological Methods. Materials. [3H]PK11195 (S.A. 85.5 Ci/mmol) and [3H]Ro15-1788 (S.A. 83.4 
Ci/mmol) were purchased from Perkin-Elmer Life Sciences. Culture medium, fetal bovine serum 
 (FBS), L-glutamine, and antibiotics were purchased from Euroclone SpA (Milano, Italy). PK11195 
and Ro5-4864 were obtained from Sigma-Aldrich. All other reagents were obtained from 
commercial suppliers. 
[3H]PK11195 Binding to Rat Kidney Mitochondrial Membranes. For binding studies, crude 
mitochondrial membranes were incubated with 0.5 nM [3H]PK11195 in the presence of a 
compound concentration range (1 pM to 10 M) in 50 mM Tris-HCl, pH 7.4, as previously 
described.25,26 For the active compounds, the IC50 values were determined and Ki values were 
derived in accordance with the equation of Cheng and Prusoff.42 
[3H]Ro15-1788 Binding to Rat Cerebral Cortex Membranes. Rat cerebral cortex membranes were 
prepared as previously described.2 After differential centrifugation, the crude membrane fraction 
obtained was subjected to washing procedures to remove endogenous GABA.43 The washed 
membranes were incubated with 0.4 nM [3H]Ro15-1788 for 90 min at 0 °C in 500 L of 50 mM 
Tris-citrate buffer, pH 7.4, as previously described.44 
Computational Studies. Homology Modeling. Recently the group of Zweckstetter released the 
NMR structure of the mouse TSPO (mTSPO) in complex with the PK11195 modulator,5 thus, 
paving the way for a better definition of the interaction mode between TSPO and its synthetic 
modulators. Our group in the last decades embarked in the discovery of new promising TSPO 
modulators, describing different ligand classes able to interact with rat TSPO (rTSPO) at the sub-
nanomolar range, with the indolylglyoxylamide class being the most promising one.25-27,29,30 
mTSPO and rTSPO share a 95% sequence identity, making mTSPO a suitable template for 
homology modeling approaches. Therefore, we decided to build a three-dimensional (3D) rTSPO 
model by using the Modeller9.13 software, and mTSPO as template (See Supplementary Figure S6 
for the sequence alignment). The final rTSPO model was subsequently used to perform docking 
studies and to rationalize the SARs of the new series of indolylglyoxylamide derivatives described 
herein.  
 Docking studies. The selected 20 rTSPO models were used to dock the new series of 
indolylglyoxylamide derivatives reported in this work. All the docking studies were performed 
employing the Glide tool implemented in Maestro9.8.36 The ligand used for the validation step of 
the rTSPO structures was represented by our lead in the new series of the indolylglyoxylamide 
(Chart 1, compound 29, Table 2). The 3D structures of 29 was generated with the Maestro 
fragment Build tool and then geometrically optimized with Macromodel.36 The rTSPO structures 
were prepared through the Protein Preparation Wizard of the Maestro 9.836 graphical user interface 
which assigns bond orders, adds hydrogen atoms, and generates appropriate protonation states. 
The docking grid box was centered on the residues lining the PK11195 binding pocket, with a grid 
box dimension equal to 24 x 24 x 24 Å (See Supplementary Figure S7). In detail the residues 
considered to center the docking grid are: A23, V26, L49, A50, I52, W107, V110, L114, A147, and 
L150 (which are conserved between the mTSPO and rTSPO, a part A110V). Finally, docking runs 
were carried out using the standard precision (SP) method. Finally, all the compounds reported in 
Tables 1-2 were docked using the refined rTSPO-29 complex applying the same docking protocol.  
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 Table 1. TSPO Binding Affinity of N,N-Dialkyl-2-(4'-substitutedphenyl)indol-3-ylglyoxylylamide 
Derivatives 8-22, 7a-f. 
N
O
R2
N
R1
O
R3H
 
 
cmpd 
 
R1 = R2 
 
R3 
 
Ki (nM)a  
     
8 (CH2)2CH3 OH 16.1 ± 1.0 
9 (CH2)3CH3 OH 25.7 ± 2.6 
10 (CH2)5CH3 OH 6.3  0.5 
11 (CH2)2CH3 NH2 44.4  5.0 
12 (CH2)3CH3 NH2 133  13 
13 (CH2)5CH3 NH2 4.2  0.4 
14 (CH2)2CH3 COOH 343 ± 10 
15 (CH2)3CH3 COOH 406 ± 4 
16 (CH2)5CH3 COOH 184  1 
17 (CH2)2CH3 OCH3 5.8  0.5 
18 (CH2)3CH3 OCH3 20.3  2.2 
19 (CH2)5CH3 OCH3 4.0  0.4 
20 (CH2)2CH3 COOCH3 3.1  0.3 
21 (CH2)3CH3 COOCH3 2.7  0.3 
22 (CH2)5CH3 COOCH3 3.3  0.3 
7ab (CH2)2CH3 H 12.2  1.0 
7bb (CH2)3CH3 H 7.5  0.7 
7cb (CH2)5CH3 H 1.4  0.2 
7db (CH2)2CH3 NO2 0.95  0.10 
7eb (CH2)3CH3 NO2 0.27  0.10 
7fb (CH2)5CH3 NO2 0.23  0.10 
Ro5-4864 (1)   23.0  3.1 
PK11195 (2)   9.3  0.5 
aThe concentration of tested compounds that inhibited [3H]PK11195 binding to rat kidney mitochondrial membranes 
by 50% (IC50)  was determined with eight concentrations of the displacers, each performed in triplicate. K i values are 
the means  SEM of three determinations.  bData taken from ref. n. 26. 
 Table 2. TSPO Binding Affinity of N,N-Dialkyl-2-arylindol-3-ylglyoxylylamide Derivatives 23-35, 7a-c, g-
j. 
N
H
NO
R1
R2
O
Ar
 
     
 
cmpd 
 
R1 
 
R2 
 
Ar 
 
Ki (nM)a   
     
23 (CH2)2CH3 (CH2)2CH3 thien-3-yl 1.2 ± 0.1 
24 (CH2)3CH3 (CH2)3CH3 thien-3-yl 2.8 ± 0.3 
25 (CH2)5CH3 (CH2)5CH3 thien-3-yl 0.89 ± 0.10 
26 (CH2)2CH3 (CH2)2CH3 p-biphenyl 0.53  0.05 
27 (CH2)3CH3 (CH2)3CH3 p-biphenyl 5.5  1.0 
28 (CH2)5CH3 (CH2)5CH3 p-biphenyl 1.8  0.2 
29 (CH2)2CH3 (CH2)2CH3 naphth-2-yl 0.31  0.04 
30 (CH2)3CH3 (CH2)3CH3 naphth-2-yl 0.54  0.06 
31 (CH2)5CH3 (CH2)5CH3 naphth-2-yl 0.52  0.06 
32 CH3 (CH2)3CH3 naphth-2-yl 0.56  0.06 
33 CH3 (CH2)4CH3 naphth-2-yl 0.37  0.04 
34 CH2CH3 (CH2)3CH3 naphth-2-yl 0.51  0.05 
35 CH2CH3 CH2C6H5 naphth-2-yl 0.51  0.05 
7ab (CH2)2CH3 (CH2)2CH3 C6H5 12.2  1.0 
7bb (CH2)3CH3 (CH2)3CH3 C6H5 7.5  0.7 
7cb (CH2)5CH3 (CH2)5CH3 C6H5 1.4  0.2 
7gb CH3 (CH2)3CH3 C6H5 53.3  4.0 
7hb CH3 (CH2)4CH3 C6H5 12.1  1.0 
7ib CH2CH3 (CH2)3CH3 C6H5 12.6  1.0 
7jb CH2CH3 CH2C6H5 C6H5 11.0  1.0 
Ro5-4864 (1)    23.0  3.1 
PK11195 (2)    9.3  0.5 
aThe concentration of tested compound that inhibited [3H]PK11195 binding to rat kidney mitochondrial membranes  
by 50% (IC50) was determined with eight concentrations of the displacers, each performed in triplicate. K i values are 
the means  SEM of three determinations.  bData taken from ref. n. 26. 
  
 
 
 
 
Figure 1. a) Binding mode of 29 (orange sticks) into the rTSPO binding site (white cartoon and 
sticks). b) Bottom view of 29 binding mode, (the TSPO structure is highlighted in blue and gray 
surfaces in this as well as in pictures c and d). c) Bottom view of 7a binding mode. d) Bottom view 
of 29 (orange sticks), 20 (purple sticks), and 26 (cyan sticks) binding modes.  
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Scheme 1. Synthesis of indolylglyoxylamide derivatives 8-16. 
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Scheme 2. Synthesis of indolylglyoxylamide derivatives 23-35. 
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Chart 1. Structures of known (1-7) and newly synthesized (8-35) TSPO ligands. Structures 7-35 
have been drawn embedded within a pharmacophore/topological model of ligand-TSPO 
interaction.25,26,28  
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